Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium, 9300
- GSK Investigational Site
-
Brasschaat, Belgium, 2930
- GSK Investigational Site
-
Bruxelles, Belgium, 1200
- GSK Investigational Site
-
Gent, Belgium, 9000
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 1X5
- GSK Investigational Site
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 4G2
- GSK Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- GSK Investigational Site
-
-
-
-
-
Brno, Czech Republic, 625 00
- GSK Investigational Site
-
Jihlava, Czech Republic, 586 01
- GSK Investigational Site
-
Olomouc, Czech Republic, 775 20
- GSK Investigational Site
-
Pardubice, Czech Republic, 532 03
- GSK Investigational Site
-
Praha 2, Czech Republic, 128 51
- GSK Investigational Site
-
Praha 5, Czech Republic, 150 08
- GSK Investigational Site
-
-
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Germany, 79110
- GSK Investigational Site
-
-
Hessen
-
Marburg, Hessen, Germany, 35043
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Neubrandenburg, Mecklenburg-Vorpommern, Germany, 17036
- GSK Investigational Site
-
Rostock, Mecklenburg-Vorpommern, Germany, 18059
- GSK Investigational Site
-
Schwerin, Mecklenburg-Vorpommern, Germany, 19055
- GSK Investigational Site
-
Wismar, Mecklenburg-Vorpommern, Germany, 23966
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Ludwigshafen, Rheinland-Pfalz, Germany, 67063
- GSK Investigational Site
-
-
Saarland
-
Homburg, Saarland, Germany, 66421
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06120
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- GSK Investigational Site
-
-
-
-
-
Kwun Tong, Hong Kong
- GSK Investigational Site
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, New Territories, Hong Kong
- GSK Investigational Site
-
Sheung Shui, New Territories, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Lahore, Pakistan
- GSK Investigational Site
-
-
-
-
-
Manila, Philippines, 1000
- GSK Investigational Site
-
Quezon, City, Philippines, 1104
- GSK Investigational Site
-
-
-
-
-
Moscow, Russian Federation, 101000
- GSK Investigational Site
-
Moscow, Russian Federation, 111538
- GSK Investigational Site
-
Moscow, Russian Federation, 117152
- GSK Investigational Site
-
Perm, Russian Federation, 614107
- GSK Investigational Site
-
St. Petersburgh, Russian Federation, 192242
- GSK Investigational Site
-
-
-
-
-
Badalona, Spain, 08916
- GSK Investigational Site
-
Barcelona, Spain, 08025
- GSK Investigational Site
-
Barcelona, Spain, 08035
- GSK Investigational Site
-
Barcelona, Spain, 08003
- GSK Investigational Site
-
La Coruña, Spain, 15006
- GSK Investigational Site
-
Mataro, Spain, 08034
- GSK Investigational Site
-
Pamplona, Spain, 31008
- GSK Investigational Site
-
Santiago de Compostela, Spain, 15706
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand
- GSK Investigational Site
-
-
-
-
Alabama
-
Fairhope, Alabama, United States, 36532
- GSK Investigational Site
-
Mobile, Alabama, United States, 36608
- GSK Investigational Site
-
Montgomery, Alabama, United States, 36106
- GSK Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- GSK Investigational Site
-
-
California
-
Arcadia, California, United States, 91007
- GSK Investigational Site
-
Glendale, California, United States, 91206
- GSK Investigational Site
-
Laguna Hills, California, United States, 92653
- GSK Investigational Site
-
Pasadena, California, United States, 91105
- GSK Investigational Site
-
-
Florida
-
Boca Raton, Florida, United States, 33067
- GSK Investigational Site
-
Melbourne, Florida, United States, 32901
- GSK Investigational Site
-
Miami, Florida, United States, 33143
- GSK Investigational Site
-
West Palm Beach, Florida, United States, 33409
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21229-5299
- GSK Investigational Site
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- GSK Investigational Site
-
-
New York
-
Mineola, New York, United States, 11501
- GSK Investigational Site
-
New Hyde Park, New York, United States, 11040
- GSK Investigational Site
-
New York, New York, United States, 10038
- GSK Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45208
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- GSK Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- GSK Investigational Site
-
Winchester, Virginia, United States, 22601
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98195
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- History of PONV (postoperative nausea and vomiting) and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain abdominal, breast, thyroid or shoulder surgery.
Exclusion criteria:
- Pregnant or breastfeeding.
- Have certain pre-existing medical conditions or take certain medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants who achieved a complete response
Time Frame: Up to 24 hours
|
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple.
Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose.
Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves").
Study participants who receive antiemetic rescue medication(s) during the initial 24 hours was considered treatment failures.
|
Up to 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"
Time Frame: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a Likert scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
The Likert scale used a range of 0-10, where 0 = no nausea and 10 = nausea as bad as it could be.
|
Up to 48 hours
|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol
Time Frame: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a categorical scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
In the categorical scale, each participant asked to rate the severity of nausea as, none: no nausea, mild: queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit (but not vomiting), that has a significant negative effect on daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others), severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities.
|
Up to 48 hours
|
|
Number of participants with first emetic event
Time Frame: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with first antiemetic rescue medication
Time Frame: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary
Time Frame: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary
Time Frame: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with chemistry data outside the reference range
Time Frame: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with hematology data outside the reference range
Time Frame: Up to 48 hours
|
Up to 48 hours
|
|
|
Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)
Time Frame: Up to 24 hours
|
Up to 24 hours
|
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to Days 6-14 visit
|
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use.
The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.
Refer to the general AE/SAE module for a list of AEs and SAEs.
|
Up to Days 6-14 visit
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Postoperative Nausea and Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Neurokinin-1 Receptor Antagonists
- Casopitant
Other Study ID Numbers
Other Study ID Numbers
- NKT102552
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Dataset Specification
Information identifier: NKT102552Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: NKT102552Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: NKT102552Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: NKT102552Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: NKT102552Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: NKT102552Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: NKT102552Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.